Cytokine Signalling Forum

Publications





November 21

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, Haaland D, Chen L, Duan Y, Zueger P, Liu J, Lippe R, Pangan AL, Behrens F.
RMD Open. 2021;7(3):e001838

Analysis of data over 56 weeks shows that efficacy responses are maintained with upadacitinib 15 mg and 30 mg. Following the publication of 12-week data from the Phase III, randomised double-blind, SELECT-PsA 1 study, earlier this year, McInnes, et al. now report the 56-week efficacy and safety data of upadacitinib 15 mg and 30 mg in patients with PsA and an inadequate response to non-biological therapy Efficacy responses and inhibition of radiographic progression were maintained with upadacitin...